Guidance for guidelines

New England Journal of Medicine

Volumn 356, Issue 4, 2007, Pages 331-333

  Steinbrook, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; RECOMBINANT ERYTHROPOIETIN;

CLINICAL PRACTICE; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE; HUMAN; LYME DISEASE; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT DECISION MAKING; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SHORT SURVEY; WORLD HEALTH ORGANIZATION;

EID: 33846411817     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp068282     Document Type: Article

References (5)

1. Field MJ, Lohr KN, eds. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990.
2. Deyo RA, Psaty BM, Simon G, Wagner EH, Omenn GS. The messenger under attack - intimidation of researchers by special-interest groups. N Engl J Med 1997;336:1176-80.
3. Hasenfeld R, Shekelle PG. Is the methodological quality of guidelines declining in the US? Comparison of the quality of US Agency for Health Care Policy and Research (AHCPR) guidelines with those published subsequently. Qual Saf Health Care 2003;12:428-34.
4. Taylor R, Giles J. Cash interests taint drug advice. Nature 2005;437:1070-1.
5. Wilensky GR. Developing a center for comparative effectiveness information. Health Aff (Millwood) 2006;25:w572-w585.